Nonmyeloablative Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

A single-center study shows improvement in disability score after transplantation for those with early and relapsing MS.

Nonmyeloablative hematopoietic stem cell transplantation (HSCT) has been hypothesized to reset the immune system and provide long-term benefit in some autoimmune diseases. Investigators now report results of a single-center, open-label, observational study in 151 patients with multiple sclerosis (MS) treated with HSCT during 1 decade: 55 as part of a standard protocol and 96 treated despite not meeting protocol criteria; 81% had relapsing-remitting MS and 19% had secondary-progressive MS. For all participants, peripheral blood stem cells were collected after administration of cyclophosphamide and filgrastim. The immunoablative regimen consisted of cyclophosphamide plus either alemtuzumab (22 patients) or thymoglobulin (129 patients). Median…

Reviewing Author

Robert T. Naismith, MD

Disclosures

Consultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Robert T. Naismith, MD

Disclosures

Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense

Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)

Nonmyeloablative Hematopoietic Stem Cell Transplantation in Multiple Sclerosis

Topics

Reviewing Author